# WIRB Copernicus Group

WIRB Copernicus Group is an Ethical Review / IRB Services based in Princeton, United States.

## Overview

- **Organization type:** Ethical Review / IRB Services
- **Headquarters:** Princeton, United States
- **Region:** North America
- **Address:** Princeton, NJ, United States
- **Founded:** 1968
- **Assets under management:** Undisclosed
- **Website:** wcgclinical.com
- **LinkedIn:** https://www.linkedin.com/company/wirb-copernicus-group

## Regulatory record

- **Reports private funds:** No

## About

WIRB Copernicus Group began in 1968 as the Western Institutional Review Board, founded to provide ethical oversight for human-subject research. It has since evolved into a clinical-services holding company spanning IRB review, regulatory consulting, and technology-enabled trial solutions. The firm operates primarily through its flagship WCG IRB and a collection of acquired subsidiaries including MedAvante, Ethical, and KMR Group. The company's strategy aggregates compliance-mandated services for drug developers, medical device manufacturers, and academic medical centers. Core offerings include central and local IRB review, biosafety committee administration, and clinical endpoint adjudication. Its consulting arm — acquired through firms like PharmaSeek and The Avoca Group — provides site qualification, quality management, and trial-acceleration services. WCG's KMR Group unit publishes the industry-standard benchmark for clinical-trial performance analytics. Arsenal Capital Partners took a controlling stake in 2012 and subsequently rolled up more than a dozen specialized service providers under the WCG brand. The platform now contracts with all top-20 global biopharma companies and over 90% of academic medical centers in the United States. Leonard Green & Partners acquired a majority interest from Arsenal in 2021, with management and minority investors remaining alongside. Donald Deieso, who joined as CEO post-Arsenal, moved to Executive Chairman in recent years as the firm integrated new leadership. WCG's structural differentiator is its quasi-regulatory positioning: IRB review is federally mandated for virtually all FDA-regulated clinical investigations, giving the platform a non-discretionary demand base. Unlike CROs that compete for trial contracts, WCG inserts itself into the compliance workflow regardless of which CRO or sponsor wins the study. This makes it a toll-taker on clinical-research spending rather than a discretionary contractor.

## Sectors

- Healthcare Services
- Life Sciences

## People

- Donald A. Deieso — Executive Chairman

## Questions

### What does WIRB Copernicus Group actually do?

WCG operates a family of companies that provide regulatory compliance and ethics review services for clinical research. Its core business is institutional review board (IRB) oversight — federally required assessments of research protocols involving human subjects. Through acquisitions, it has expanded into biosafety review, endpoint adjudication, site qualification, and clinical-trial benchmarking analytics.

### How does WCG differ from a contract research organization?

A CRO like IQVIA or Parexel wins contracts to conduct clinical trials; WCG provides compliance infrastructure that sponsors and CROs are required to use irrespective of which organization runs the trial. Its revenue is tied to the number of protocols submitted for regulatory review rather than to discretionary trial-outsourcing decisions, giving it different exposure to R&D budget cycles.

### Which types of institutions rely on WCG's services?

WCG serves biopharmaceutical companies, medical device manufacturers, contract research organizations, and academic medical centers conducting FDA-regulated human-subject research. The company reports contracting relationships with all top-20 global biopharma companies and more than 90% of US academic medical centers.

### What is KMR Group's role within WCG?

KMR Group, acquired by WCG, publishes the industry's most widely cited benchmarks for clinical-trial site performance and cycle-time analytics. Its data set covers thousands of trials across therapeutic areas, and its reports are used by sponsor organizations to evaluate how their development timelines and costs compare with industry norms.

## Related profiles

- [A100x Ventures](https://altss.com/profile/a100x-ventures)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/wirb-copernicus-group

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology